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Implantable cardioverter-deﬁbrillators (ICDs) improve the survival in patients at risk of sudden cardiac
death. However, these patients have an ongoing risk of sudden incapacitation that may cause harm to
individuals and others when driving. Considerable disagreement exists about whether and when these
patients should be allowed to resume driving after ICD therapies. This information is critical for the
management decisions to avoid future potentially lethal incidents and unnecessary restrictions for ICD
patients. The cardiac implantable device committee of the Japanese Heart Rhythm Society reassessed the
risk of driving for ICD patients based on the literature and domestic data. We reviewed the driving
restrictions of ICD patients in various regions and here present updated Japanese driving restrictions.
& 2017 Japanese Heart Rhythm Society. Published by Elsevier B.V Japanese Heart Rhythm Society. This is
an open access article under the CC BY-NC-ND license
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abe).1. Introduction
Implantable cardioverter-deﬁbrillators (ICDs) improve survival
in patients who have been resuscitated from ventricular ﬁbrilla-
tion (VF) or ventricular tachycardia (VT) (i.e., secondary prevention
of sudden cardiac death) as well as primary prevention of suddeneart Rhythm Society. This is an open access article under the CC BY-NC-ND license
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with ICDs in Europe (EU) and the United States (US) [1] and [2].
The Japan Arrhythmia Device Industry Association (JADIA) repor-
ted that 5789 and 5969 ICDs and cardiac resynchronization
therapy with deﬁbrillators (CRT-Ds) were implanted in 2014
and 2015, respectively [3]. From 2006 to 2016, approximately
60,000 patients have been implanted with ICDs or CRT-Ds [3].
Most ICD patients may be healthy enough to drive a motor
vehicle. However, patients with ICDs are known to experience
complete or partial loss of consciousness. The privilege of driving
is cherished, but driving restrictions are necessary when it poses a
threat to others. According to literature, the rate of syncope or loss
of consciousness associated with ICD therapy varies widely [4–9]
and [10]. Many countries have regulations for driving restrictions
in ICD patients, but large varieties exist between countries [11–15]
and [16]. These large varieties are due to the lack of information
about the rate of syncope while driving, which results in serious
harm or death in ICD patients.
The cardiac implantable device committee of the Japanese
Heart Rhythm Society reassessed the risk of driving in ICD
patients based on the literature and domestic data. We reviewed
the driving restrictions of ICD patients in various regions and
present a revised regulation of the Japanese driving restrictions.
This information is critical for the management decisions to avoid
future potentially lethal incidents and unnecessary restrictions
for ICD patients.2. Syncope while driving a motor vehicle
Syncope is a common clinical problem, with an incidence rate
of 6.2 per 1000 person-years in the Framingham study [17], and is
often recurrent [18]. Syncope while driving has evident personal
and public implications, but data on the causes and outcome of
syncope while driving are scarce. Previous observational studies
reported that the most frequently identiﬁed causes are neurally
mediated syncope, followed by tachycardic or bradycardic
arrhythmias, and orthostatic hypotension [19] and [20]. Among
the arrhythmias in these patients, supraventricular tachycardia
and VT are more frequently observed than bradycardia [19] and
[20]. Notably, the recurrence rate of syncope while driving is only
0.7% at 6 months and 1.1% at 12 months. Furthermore, most of
these patients with syncope while driving have had an underlying
diagnosis of not arrhythmia but neurally mediated syncope. These
data suggest that patients with syncope while driving can resume
driving with a relatively low risk of harm to drivers and bystanders
[21] and [22].3. Driving-related arrhythmias and ICD discharges while
driving
Driving brings mental and physical stress. It causes an
increased heart rate, blood pressure, and peripheral resistance
through elevated sympathetic activity [23]. An early study showed
that signiﬁcant ST depression and T wave changes develop while
driving in patients with ischemic heart disease [24]. This study
also showed that even healthy subjects have signiﬁcant ST–T
changes while driving. Such elevated sympathetic activity while
driving is expected to lead to an increased propensity for
arrhythmias. However, only a few studies have examined driving-
related arrhythmias.
An early study by Trappe et al. [6] showed that 8 out of 241
ICD patients (5%) had ICD shocks while driving but they were not
associated with syncopal symptoms. Only one accident was
caused by the driver, but it was not related to syncopal symptomsor an ICD therapy. The Antiarrhythmics Versus Implantable
Deﬁbrillators (AVID) trial, which compared the survival beneﬁt
between antiarrhythmic drug therapy and ICDs in patients who
had been resuscitated from VT or VF, showed that 8% of 295
patients had ICD shocks while driving but they were not related
to accidents [8] and [25].
The triggers of ventricular arrhythmia study [26] compared the
risk of the occurrence of VT/VF during and up to 60 min after
driving with that during other activities among 1188 ICD patients.
Of the 193 total ICD shock episodes for VT or VF, 44 occurred
within 1 h of driving a car among 23 patients. Of the 44 ICD shocks
that occurred within 1 h of driving, 7 (16%) occurred during driv-
ing, 30 (68%) occurred 30 min immediately after beginning driv-
ing, and 7 (16%) occurred during the last 30-min period. An ICD
shock for VT or VF was twice as likely to occur within 1 h of driving
a car as compared with that during other activities or rest. How-
ever, none of the shocks for VT or VF that occurred while driving
resulted in lightheadedness or syncope, and only 1 resulted in an
automobile accident. Patients who received ICDs for primary
prevention were shown to less likely to abstain from driving
compared with secondary prevention.
According to an early survey in 452 physicians in the US, 30
motor vehicle accidents related to shocks from ICDs occurred over
a 12-year period from 1980 to 1992 [27]. Eight patients died due to
loss of consciousness with the device ﬁring while the patient was
driving, and one passenger died in a vehicle driven by a patient
with an ICD. This survey found that 10.5% (30 of 286 total reported
shocks) of ICD shocks during driving resulted in accidents. The
authors estimated the fatality rate for patients with an ICD of 7.5/
100,000 patient-years, which was signiﬁcantly lower than that for
the general population (18.4/100,000 patient-years, po0.05).
Few studies have speciﬁcally examined the incidence of ICD
discharges while driving in patients receiving ICDs for primary
prevention. However, the low frequency of ICD shocks and very
low rate of syncopal episodes reported in the recent primary
prevention ICD trials [9,28–30] and [31] suggest that the incidence
rate of ICD shocks while driving may be lower than that in sec-
ondary prevention patients. Furthermore, strategic arrhythmic
programs, including higher detection rates, longer detection
intervals, antitachycardia pacing, and optimized supraventricular
tachycardia discriminators, reduce ICD shocks without increasing
arrhythmic syncope among ICD patients for primary prevention
[9,28–30] and [31]. Taken together, this evidence suggests that ICD
patients should not translate into a signiﬁcant rate of personal or
public injury.4. Risk assessment of patients and bystanders
The effect of an ICD shock delivery on the level of conscious-
ness and ability to drive is an obvious concern. Data regarding the
risks associated with driving in ICD patients are primarily retro-
spective, with no prospective, randomized trials dividing patients
into driving with or without restrictions. The “risk of harm (RH)”
analysis provided useful information for future consideration of
driving to improve the public safety for both the patients and
general public.
The Canadian Cardiovascular Society Consensus Conference
postulated an RH formula [32] to quantify the level of risk to
drivers and bystanders according to the Ontario Road Safety
Annual Report [33]. This formula has been used in many other
reports to provide the policy for driving restrictions [14,22,34,35]
and [36]. The risk of harm formula is shown below:
RH¼ TD V  SCI Ac;
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driver with heart disease.
(1) TD equals the proportion of time the patient spends driving
during the year, which is 0.04 (4%, 1 h/day) for the private
driver and 0.25 (25%, 6 h/day) for the commercial driver [33].
(2) V is a vehicle-speciﬁc constant based on the type of vehicle
driven. In the RH formula, it is deﬁned that V¼1 for a
commercial heavy truck and V¼0.28 for a standard-size
passenger car.
(3) SCI is the annual probability of sudden cardiac incapacitation,
which is estimated to be 0.01 (1%/year) by the Canadian Car-
diovascular Society and the Canadian Council of Motor
Transport Administrators.
(4) Ac is the probability of injury or an accident after the SCI and
is estimated to be 0.02 for all drivers. Substituting these values
in the RH formula results in the following risk:
RH¼ TD V  SCI Ac¼ 0:25 1 0:01 0:02¼ 0:005:
The Canadian Cardiovascular Society and the Canadian Council
of Motor Transport Administrators proposed an annual RH to
others of 5 in 100,000 (0.005%) as a cut-off value.
The RH while driving after the ﬁrst ICD shock for private
drivers is estimated as follows. For example, the cumulative
incidence of second shock at 6 months is 10% (0.1); the inci-
dence at 6 months is multiplied by 2 to obtain an annual risk
(0.112/6¼0.2) because the RH formula uses the annual risk
for SCI. The risk for SCI is then estimated by multiplying
the annual risk for receiving a second ICD shock (0.2) by the
probability of syncope associated with a shock (i.e., 0.3),
(0.20.3¼0.06). Then, the RH¼0.040.280.060.02¼1.3/
100, 000, which is below the acceptable level of 5/100, 000.
However, for the commercial truck driver, the RH¼TD (0.25)V
(1) SCI (0.06)Ac (0.02)¼30/100, 000, which exceeds the
acceptable level. Therefore, commercial drivers are not certiﬁed
for commercial driving if they have received ICDs.5. Deﬁnition of private drivers and commercial (professional)
drivers
In Japan, class 1 driver's license (private drivers) is deﬁned as
any licensed driver of ordinary motorcycle, automobiles, and other
vehicles with or without a trailer, and does not earn a living by
driving. A commercial driver (class 2 driver's license) is deﬁned as
one who drives for a business (commercial operation) including a
taxi, bus, or private ambulance. Those who received ICDs can drive
an ordinary automobile weighing o5000 kg, but cannot drive
motorcycles or passenger-carrying vehicles. There are no restric-
tions in the time spent behind the wheel or distance driven in a
given time period. In Canada, a private driver is deﬁned as one
who drives o36,000 km/year or spends o720 h/year behind the
wheel, drives a vehicle weighing o11,000 kg, and does not earn a
living by driving. A commercial driver is deﬁned as any licensed
driver who does not fulﬁll the deﬁnition of a private driver [37]
and [38]. In EU, Group 1 (private drivers) is comprised of drivers of
ordinary motorcycles, cars, and other small vehicles with or
without a trailer. Group 2 (professional drivers) includes drivers of
vehicles over 3.5 metric tons or passenger-carrying vehicles
exceeding eight seats excluding the driver [14] and [16]. In the US,
a commercial driver is deﬁned as one who drives any single
vehicle with a weight of 26,001 pounds or more, truck with double
or triple trailers, or truck with a tank, or a truck carrying hazar-
dous materials. It also includes a passenger vehicle designed to
transport 16 or more passengers (including the driver) [39] and[40]. There are subclasses of private and commercial drivers in
each state.6. Risk of harm and driving restrictions for private drivers
(secondary prevention patients)
As presented in the previous section, the factors that affect the
RH are the recurrence rate of ICD shock, and the probability of a
loss of consciousness associated with an ICD shock while driving.
Given the limited data on the probability of ICD shocks while
driving associated with syncopal symptoms, we used the syncope
rate associated with ICD shocks instead (not limited to a shock
while driving). According to the literature that included mainly
secondary prevention patients, the mean incidence rate of syncope
associated with appropriate ICD shocks was 11.2% (Fig. 1).
Thijssen et al. [35] calculated the annual RH to others posed by
a driver with an ICD using 2786 patients (primary prevention
62%). When a syncope rate of 32% associated with an ICD shock
was used, the RH fell below the accepted threshold (0.005%) at
2 months after an initial shock in the primary prevention group
and at 4 months after an initial shock in the secondary preven-
tion group. Recently, Merchant et al. [36] reported an RH using
large data extracted from remote monitoring systems. They
examined the 73,503 ICD recipients who were followed by a
remote monitoring system and analyzed 14,230 (19.4%) patients
who experienced at least 1 ICD shock. When a frequency of
syncope of 32% associated with an ICD shock was used [7] and
[35], the RH fell below the accepted threshold (0.005%) at 4–6
months after the initial shock. However, the use of a con-
temporary estimate for syncope associated with an ICD shock of
14% [36] showed that the RH fell below the threshold at 1 month
after the initial shock. We calculated the RH while driving in the
Japanese ICD survey 2 using a likelihood of syncope of 9.5%
(Fig. 2). We found that the RH fell below the accepted threshold
(0.005%) at 3 months after an initial shock. Based on the evidence
and these calculations, current restrictions on driving advise
patients with an ICD implanted for secondary prevention to avoid
operating a motor vehicle for 3 months for Japan and EU [14] and
6 months after the last ICD shock in the US [11,12] and [13] and
UK [16] (Table 1). In the UK, refraining from driving for 1 month
after the initial implantation is recommended in secondary pre-
vention patients who have sustained VT with incapacity. In
addition, avoidance of driving for at least 6 months after an initial
implantation is recommended in Japan, the US [13], and the UK
[16], and 3 months in EU [14] (Table 1).7. Risk of harm and driving restrictions for private drivers
(primary prevention patients)
Patients with ICDs for primary prevention are considered at
lower risk for sudden incapacitation while driving compared with
the secondary prevention population. We summarized the syn-
cope rate and patient characteristics in recent reports aimed to
assess strategic programming in mainly primary prevention
patients (Fig. 3). The mean incidence rate of syncope was calcu-
lated to be 1.6%, which was approximately one-tenth of that in the
secondary prevention patients. Patients who have received an ICD
for primary prevention who subsequently receive an appropriate
therapy for VT or VF should be considered to be subject to the
driving guidelines like secondary prevention. In addition, avoid-
ance of driving for at least 7 days after the initial implantation to
allow for healing has been recommended in Japan and the US [13],
and 1 month for the UK [16] and EU [14] (Table 1).
Fig. 1. Incidence rate of syncope associated with appropriate ICD therapies in secondary prevention patients. Literature reported incidence rates of syncope associated with
appropriate ICD shock deliveries are presented in a chronological order. These earlier studies primarily included more secondary prevention patients. The mean value of the
seven studies (Kou [4], Bansch [5], Trappe [6], Freedberg [7], Klein [8], Lerecouvreux [56], and the Japanese survey for appropriate ICD therapies (Japanese ICD survey 2)) was
11.2%. In the Japanese ICD survey 2, the appropriate ICD therapy event data between 1997 and 2014 from 58 Japanese institutions were analyzed retrospectively (unpublished
data). In brief, 1415 appropriate ICD therapies (ATP, cardioversion, and deﬁbrillation for VT/VF) occurring in 886 patients (age 65714 years, secondary prevention 63%) were
analyzed. For the second therapy analysis, only a subsequent inappropriate therapy occurring 424 h after the ﬁrst inappropriate shock was considered a second therapy. A
total of 532 (60%) experienced a second appropriate therapy during a follow-up period of 3.6 years. ICD: implantable cardioverter-deﬁbrillator, ATP: antitachycardia pacing,
VT: ventricular tachycardia, VF: ventricular ﬁbrillation.
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Fig. 2. Annual risk of harm from appropriate ICD therapies in a Japanese survey.
The annual risk of harm in ICD patients based on the cumulative incidence of
appropriate ICD therapies is illustrated. In the Japanese survey for appropriate ICD
therapies (Japanese ICD survey 2), the annual RH to others was lower than 5 in
100,000 at 3 months after the ﬁrst shock. The syncope rates of 32% and 14% were
reproduced from Merchant et al. [36].
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vers (both primary and secondary prevention patients)
For commercial drivers, incapacitation while driving places the
driver and bystanders at that time in serious jeopardy. In view of
the RH, the risk of commercial drivers exceeds an accepted
threshold (0.005%). Therefore, all four driving restrictions pre-
sented in this review recommend permanent prohibition of
commercial driving after an ICD implantation for secondary and
primary prevention (Table 1).9. Driving restrictions after inappropriate ICD therapies
The driving restrictions after inappropriate ICD therapies differ
among countries. This difference is probably due to the not well
known incidence of syncope or loss of consciousness with inap-
propriate shocks. The ICD can provoke or worsen arrhythmias (i.e.,
proarrhythmia) that may result in syncope [41] and [42]. We
analyzed inappropriate ICD therapy event data from 50 Japanese
institutions (Japanese ICD survey 1, unpublished data). A total of
772 inappropriate ICD therapies occurring in 417 patients (age
61715 years, primary prevention 65%) were examined. Patients
experiencing an inappropriate therapy had a mean number of
1.871.5 therapy episodes during the mean follow-up period of
5.2 years. Only 3 patients (0.7%) experienced syncope associated
with inappropriate therapies. The RH formula revealed that the
annual RH to others was 0.16 in 100,000 immediately after an
onset of inappropriate therapy, which was far below the accep-
table level of 5 in 100,000.
Previous Japanese driving restrictions for ICD patients advised
no driving for 12 months after receiving either an appropriate or
inappropriate therapy [15]. However, based on the data described
above, the current driving restrictions advise that private drivers
do not have to refrain from driving after receiving an inappropriate
ICD therapy if it was not associated with a loss of consciousness
(Table 1). However, if drivers lost consciousness at the time of the
inappropriate therapy, they should abstain from driving for
3 months. In the US, a private driver has to cease from driving for
6 months after receiving an inappropriate therapy and no differ-
ence exists in the restriction between appropriate and inap-
propriate therapies [43]. In the UK, a patient has to refrain from
driving for 1 month after the cause of the inappropriate therapy
has been corrected [16]. In EU, no period of time is set but the
Table 1
Driving restrictions in patients with ICD and pacemaker in four regions.
License type Japan UK USA EU
Pacemaker implant Class 1 Cease driving for 1 week Cease driving for 1 week Cease driving for 1 week Cease driving for 1 week
Class 2 Disqualiﬁed until pacemaker integrity is
ascertained.
Cease driving for 6 weeks Cease driving for 4 weeks Disqualiﬁed if persistent symptoms.
ICD implant for VT/VF with inca-
pacity (secondary prevention)
Class 1 Cease for 6 months after ﬁrst implant Cease for 6 months after ﬁrst implant Cease for 6 months after ﬁrst
implant
Cease for 3 months
Class 2 Permanently bars Permanently bars Permanently bars Permanently bars
ICD implant for sustained VT
without incapacity (secondary
prevention)
Class 1 Cease for 6 months after ﬁrst implant Cease for 1 month after ﬁrst implant provided all of
the following are met:
Cease for 6 months after implant Cease for 3 months after implant
(a) LVEF 435%
(b) No fast VT on EPS
(c) Any induced VT could be pace-terminated by the
ICD twice, without acceleration, during the post-
implantation study.
Class 2 Permanently bars Permanently bars Permanently bars Permanently bars
Prophylactic ICD implantation
(primary prevention)
Class 1 Cease for 1 week Cease for 1 month Cease for 1 week Cease for 4 weeks
Class 2 Permanently bars Permanently bars. Permanently bars Permanently bars.
ICD and lead system replacement Class 1 Cease for 1 week after replacement of the
lead system or replacement of the ICD.
Cease for 1 month after a revision of the leads or
antiarrhythmic drug change.
No speciﬁc guidance Cease for 4 weeks after replacement of
the ICD and lead system or the lead
system alone.
Cease for 1 week after replacement of
ICD.
Delivery of ICD therapy Class 1 Cease for 3 months after appropriate
therapy
Appropriate shockþsymptomatic ATP: Cease for 6 months after appro-
priate therapy
Cease for 3 months after appropriate
therapy
Inappropriate therapy: no restrictions for
asymptomatic episodes. Cease for
3 months in case of syncope.
Cease for 6 months with corrective measures to pre-
vent recurrence provided no further symptomatic
therapy
Inappropriate therapy: no dis-
tinction made from appropriate
therapy.
Inappropriate therapy: cease until
cause of inappropriate therapy was
corrected.
Inappropriate therapy: cease for 1 month after the
cause of the inappropriate therapy was corrected.
Adapted from References [11–16], and [34].
ICD: implantable cardioverter-deﬁbrillator, ATP: antitachycardia pacing, VT: ventricular tachycardia, VF: ventricular ﬁbrillation, LVEF: left ventricular ejection fraction, EPS: electrophysiologic test.
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Fig. 3. Incidence rate of syncope associated with appropriate ICD therapies in primary prevention patients. Literature has reported the incidence rate of syncope associated
with appropriate ICD shock deliveries sorted in a chronological order. These studies aimed to examine the effect of strategic programming mainly for primary prevention
patients. The mean value of the ten studies (Pain Free I [57], Pain Free II [58], Comparison of Empiric to Physician-Tailored Programming of ICDs (EMPIRIC) [59], Primary
Prevention Parameters Evaluation (PREPARE) [28], PITAGORA [60], Role of Long Detection Window Programming in Patients With Left Ventricular Dysfunction, Non-
ischemic Etiology in Primary Prevention Treated with a Biventricular ICD (RELEVANT) [29], Avoid Delivering Therapies for Nonsustained Arrhythmias in ICD Patients III
(ADVANCE III) [61], Buber [9], Multicenter Automatic Deﬁbrillator Implantation Trial—Reduce Inappropriate Therapy (MADIT-RIT) [30], and Programming Implantable
Cardioverter-Deﬁbrillators in Patients with Primary Prevention Indication to Prolong Time to First Shock (PROVIDE) [31]) was 1.6%.
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therapy is corrected (Table 1) [14].10. Replacement of ICD and lead system
In Japan, a driving restriction of 1 week is recommended when
an ICD or lead system is replaced and the system integrity should
be ascertained before resumption of driving (Table 1). The task
force of EU recommends a driving restriction for 1 week when
only the ICD is replaced. The UK recommends a driving restriction
for 1 month after a revision of the leads or antiarrhythmic drug
change [14] and [16]. The US does not have a speciﬁc guidance for
driving restriction after replacement of ICD and lead system.11. Pacemakers
In Japan, 1 week before resumption of driving following a
pacemaker implantation (including cardiac resynchronization
therapy pacemaker) or generator replacement is recommended
to allow healing for private drivers [44,45], which is similar to
those in the US [45] and EU [18]. Commercial drivers should be
disqualiﬁed until the pacemaker integrity was ascertained [44]
(Table 1).12. Adherence to driving restrictions after ICD therapies
Driving a motor vehicle plays an important role in emotional
and economic health, and a driving ban impacts one's QOL [46].
ICD recipients perceive a loss of independence and changed self-
image when they have restrictions of driving [47]. Several studiesreported a low adherence rate among ICD recipients to the driving
ban despite advice by physicians or healthcare providers [25,48–
50] and [51]. The AVID Trial [50] showed that the majority of
patients (58%) resumed driving an automobile within 6 months of
their index arrhythmia. They found that being younger than 65
years of age, college educated men, and those whose index
arrhythmia was VT were more likely to resume driving early.
Carney et al. [49] examined the factors that inﬂuence the
resumption of driving despite a driving ban instruction by their
physician. In this study, 74% of the 97 patients reported driving an
average of 60 min/week. They found that factors related to driving
resumption were an importance of driving to maintaining one's
lifestyle, driving for necessity for social reasons, and being the
primary driver in the family. Therefore, well-informed discharge
education and scheduled follow-up of patients are essential to
maintain higher adherence to the driving restrictions. In Japan, a
legal regulation exists for driving for ICD recipients. The recipients
must submit a medical certiﬁcate, which includes the ICD therapy
status, to the National Public Safety Commission every 6 months to
drive an automobile. They will be punished if an accident occurs
while driving despite an order for a driving ban by their physician.13. Automobile accidents in the elderly
Most of the ICD patients were elderly. In the Japanese ICD
Survey 2 data, approximately 70% of patients were aged 60 and
older (Fig. 4). In 2015, there were approximately 24 million
licensed drivers aged 60 and older in Japan, which comprised
29.4% of all licensed drivers [52]. Trafﬁc accidents have decreased
over the past 10 years (0.60 times in 2004), but accidents due to
elderly drivers have been high (1.07 times the same) because of
the increase in the number of elderly driver licenses [53]. Since
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Fig. 4. Age distribution of the ICD recipients and motor vehicle accidents in Japan.
The age of the ICD recipients in our ICD survey 2 and motor vehicle accidents in
Japan in 2014 are shown. The number of ICD recipients increases in proportion to
an advancing age, but the rate of motor vehicle accidents has relatively decreased
in the population of more than 70 years old.
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voluntarily returning persons have been rapidly increasing,
exceeding 100,000 in 2012 and exceeding 200,000 in 2014. It
doubled in only two years. One of the reasons for the increased
voluntary repayment is “preferential treatment of voluntary
repayers.” For example, free delivery to homes by some grocery
shops, discounts at restaurants for eating and drinking, and
preferential treatment by public transportation systems, such as
buses and taxis, are also available. Furthermore, since 2017, if
drivers over 75 years of age have a trafﬁc accident, they will have
to consult a doctor afterwards. If it is diagnosed as cognitive
impairment, it will be subject to cancellation or suspension of
one's driver's license.
Most of the seniors are characterized by physical changes that
may affect serious accidents. These involve a slower reaction time,
depth perception change, vision and hearing problems, decreased
ability to focus, and medical problems [54]. Compared with acci-
dents caused by young people, accidents due to safety uncertainty
for elderly people are particularly high. In Japan, renewal of dri-
ver's license of a person over 70 years of age requires attendance
of an “Elderly Personnel Course” before the renewal procedure. In
brief, this lesson includes a lecture on trafﬁc law or trafﬁc accident
statistics, driving aptitude test, and actual vehicle driving, among
others. The National Center for Geriatrics and Gerontology in Japan
and an automobile school jointly developed a lecture curriculum
to improve the safety of driving in elderly people. When tested in
the elderly with a decline in cognitive function, the ability for safe
driving, including one's attention and judgment, greatly improved,
and the effect was sustained even after one year [55].14. Conclusions
The safety of driving in patients with cardiac arrhythmias is a
common concern. All guidelines or statements of the four areas we
examined suggest that most ICD patients can resume driving after
appropriate or inappropriate shocks with a relatively low risk of
harm to themselves and others. It should be emphasized that the
risk while driving is mainly a consequence of the underlying heart
disease (acute coronary syndrome or heart failure, etc.) and not
the presence of an ICD. Driving restrictions are necessary to pro-
tect the society from harm, but the lifestyle or QOL of ICD patients
should be maintained as well. Therefore, adequate education of
driving restrictions for ICD patients and their families is indis-
pensable to comply with driving recommendations. Innovations,such as self-driving technologies, may be a promising approach to
mitigate driving restrictions for the ICD recipients.Conﬂict of interest
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